Skip to content

Castle Biosciences CSTL Investment Proceeds

Investment Proceeds at other companies

Personalis, Inc. logo
Personalis, Inc.PSNL
$24.1M-45.5%
NeoGenomics logo
NeoGenomicsNEO
$0-100%
GeneDx Holdings logo
GeneDx HoldingsWGS
$875K
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$0
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$0-100%
TEC
Bio-TechneTECH
$1.09M-95.4%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's investment proceeds?
Castle Biosciences (CSTL) reported investment proceeds of $2.68M in Q1 2026.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.